Pharmotech SA focuses its Research and Development (R&D) on the potential application of cannabinoids as antibiotic agent against Multi Drug Resistant bacteria (MDR-MRSA) as Pseudomonas Aeruginosa (PA).

We have the best and vastest laboratory just around us: Nature. It is fascinating for us to re-discover its secrets.

Switzerland is a country with several positive facets, being one of them its topnotch worldwide recognized Universities and laboratories. For this reason Pharmotech SA is conducting its R&D in collaboration with Swiss Primary Scientific Institutions. During our last R&D protocols we confirmed some of CBD’s already suspected pharmacological properties and we have additionally found a totally new one. This discovery will certainly help elevate the quality of life of millions of people world wide. Pharmotech SA is conducting its R&D with the main target being the creation of a number of natural CBD based drugs. 

To translate scientific discoveries from the lab bench to the clinic, Pharmotech SA will use proof-of-concept clinical trials to obtain clinical data (small scale studies used to get an early read on a drug’s safety and effectiveness) to help find and advance the most promising drug candidates. These proof-of-concept studies often focus on treating well-defined disease.

Pharmotech SA since 2014 continues actively its R&D program and is following all the steps needed to go on the market. The subjects of the studies are reserved. 


Pharmotech Team

It's only fair to share...Email this to someone
Share on Facebook
Tweet about this on Twitter
Share on LinkedIn
Pin on Pinterest